Blogger Facebook Twitter You Tube RSS

Prevention and Treatment Method for Protozoan Infections

Utah State University is seeking innovative companies interested in promoting public health through the prevention and treatment of protozoan infections such as cryptosporidiosis, leishmaniasis, Chagas disease and malaria. The World Health Organization predicts a child dies from malaria every 30 seconds. Moreover, according to the Center for Disease Control and Prevention, leishmaniasis affects over 1.5 million people world wide and cryptosporidiosis—more commonly known as “Crypto”—is one of the most common waterborne diseases in the US. Researchers at Utah State University have developed a method to control or prevent such protozoan infections caused by vector borne parasites through therapeutically effective amounts of natural product cyclic lipodepsipeptides. With the resistance to protozoan drugs and the susceptibility of small children, the elderly, and persons with lowered immune systems to protozoan infections, the market opportunities for treatment are increasing rapidly.
Features and Benefits
  • Therapeutic treatment of protozoan infections such as:
    • Cryptosporidiosis
    • Malaria
    • Leishmaniasis
  • Trypanosomiasis (Chagas disease)
  • Prevention of infection in immune compromised subjects
  • Alleviate protozoan drug resistance
  • Treats infections in immune compromised subjects, saving the lives of children, the elderly and the ill
  • Controls infections caused by protozoans, decreasing the spread of disease
  • Alleviates protozoan drug resistance, innovating the treatment of protozoan infections
Treatment for protozoan infections range from conventional chemotherapy to pharmaceuticals, but these treatments are losing their utility because of the development of drug resistance. A new treatment method has been formulated at Utah State University to combat protozoan infections and their drug resistance. The new method uses a family of cyclic lipodepsipeptides to prevent and more effectively treat infection.
Development Stage
Prototype cyclic lipodepsipeptides (Syringomycin-E and syringostatin A) are developed, patented, and ready for clinical studies. An axenic amastigote in vitro screen of syringomycin E and syringostatin A IC50 values in the dose-response curves were 317 ng/ml and 253 ng/ml, respectively.
U.S. Patent No. 6,310,037
Berry Treat
Senior Commercialization Associate
Life Sciences
(435) 797-4569
Reference: W98097